Jazz Pharmaceuticals (JAZZ) Profit After Tax (2010 - 2026)

Jazz Pharmaceuticals' Profit After Tax history runs 17 years deep, the most recent figure standing at $293.1 million for Q1 2026.

• In Q1 2026, Profit After Tax rose 416.86% year-over-year to $293.1 million; the TTM figure through Mar 2026 stood at $29.5 million (down 93.88% YoY), while the FY2025 annual figure was -$356.1 million, down 163.58% from the prior year.
• Profit After Tax for Q1 2026 stood at $293.1 million, up from $203.5 million in the prior quarter.
• The five-year high for Profit After Tax was $293.1 million in Q1 2026, with the low at -$718.5 million in Q2 2025.
• The 5-year median for Profit After Tax is $113.4 million (2023), against an average of $11.6 million.
• The sharpest annual moves came in 2022 and 2023: Profit After Tax tumbled 580.95% in 2022, then soared 8720.83% in 2023.
• Jazz Pharmaceuticals' Profit After Tax stood at -$240.7 million in 2022, then surged by 139.11% to $94.2 million in 2023, then surged by 102.98% to $191.1 million in 2024, then climbed by 6.45% to $203.5 million in 2025, then surged by 44.06% to $293.1 million in 2026.
• Business Quant data shows JAZZ's Profit After Tax at $293.1 million in Q1 2026, $203.5 million in Q4 2025, and $251.4 million in Q3 2025.